The promise of RNA-based therapeutics in revolutionizing heart failure management - a narrative review of current evidence.
RNA-based therapeutics
heart failure
patient outcomes
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
01
07
2023
accepted:
18
07
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
This review elucidates the potential of RNA-based therapeutics to revolutionize heart failure (HF) management. Through a comprehensive analysis of relevant studies, this review reveals the promising prospects of these novel interventions in personalized treatment strategies, targeted modulation of specific molecular pathways, and the attainment of synergistic effects via combination therapies. Moreover, the regenerative capacity of RNA-based therapeutics for cardiac repair and the inherent advantages associated with noninvasive routes of administration are explored. Additionally, the studies accentuate the significance of diligent monitoring of disease progression and treatment response, ensuring safety and considering long-term outcomes. While ongoing research endeavours and technological advancements persist in addressing extant challenges and limitations, the transformative potential of RNA-based therapeutics in HF management offers a beacon of hope for enhanced patient outcomes.
Identifiants
pubmed: 37663746
doi: 10.1097/MS9.0000000000001118
pii: AMSU-D-23-01427
pmc: PMC10473317
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
4442-4453Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Références
Nat Rev Cardiol. 2021 Jun;18(6):389-399
pubmed: 33500578
Eur Heart J. 2001 Aug;22(15):1318-27
pubmed: 11465964
Nucleosides Nucleotides Nucleic Acids. 2020;39(1-3):292-309
pubmed: 31509065
Mol Med Rep. 2019 Feb;19(2):994-1003
pubmed: 30569169
Mol Ther. 2019 Apr 10;27(4):785-793
pubmed: 30611663
Mol Diagn Ther. 2022 Jan;26(1):117-127
pubmed: 34994962
BMC Biotechnol. 2021 Mar 10;21(1):20
pubmed: 33691652
Adv Mater. 2020 Jan;32(1):e1904905
pubmed: 31743531
ESC Heart Fail. 2014 Sep;1(1):4-25
pubmed: 28834669
Signal Transduct Target Ther. 2022 May 21;7(1):166
pubmed: 35597779
Nature. 2008 Dec 18;456(7224):980-4
pubmed: 19043405
J Am Coll Cardiol. 2020 Apr 21;75(15):1788-1800
pubmed: 32299591
Eur J Heart Fail. 2016 Apr;18(4):414-23
pubmed: 26345695
PLoS One. 2015 Oct 05;10(10):e0139504
pubmed: 26436892
Kaohsiung J Med Sci. 2018 Nov;34(11):626-633
pubmed: 30392569
Nat Biotechnol. 2022 Nov;40(11):1586-1600
pubmed: 36329321
Fam Pract. 2017 Apr 1;34(2):161-168
pubmed: 28137979
J Clin Med. 2020 Jun 26;9(6):
pubmed: 32604776
Circulation. 2009 Mar 10;119(9):1241-52
pubmed: 19237664
Nucleic Acids Res. 2020 Sep 25;48(17):9840-9858
pubmed: 32870273
Circulation. 2016 Jan 26;133(4):e38-360
pubmed: 26673558
Mol Med. 2021 Jul 8;27(1):72
pubmed: 34238204
Mol Biotechnol. 2008 Mar;38(3):257-68
pubmed: 17999201
Circulation. 2016 Oct 11;134(15):1085-1099
pubmed: 27630136
Nat Rev Mater. 2021;6(12):1078-1094
pubmed: 34394960
Biomedicines. 2021 Apr 16;9(4):
pubmed: 33923688
Nucleic Acids Res. 2016 Aug 19;44(14):6549-63
pubmed: 27288447
Cell Death Dis. 2022 Jul 23;13(7):644
pubmed: 35871216
Nat Rev Cardiol. 2021 Jun;18(6):400-423
pubmed: 33432192
PLoS One. 2014 Oct 09;9(10):e108625
pubmed: 25299183
Mol Ther. 2019 Apr 10;27(4):794-802
pubmed: 30655211
Genome Med. 2017 Jun 27;9(1):60
pubmed: 28655327
Eur Heart J. 2021 Jan 7;42(2):178-188
pubmed: 33245749
Eur J Pharmacol. 2021 Aug 15;905:174178
pubmed: 34044011
Nucleic Acids Res. 2020 Feb 28;48(4):1691-1700
pubmed: 31980820
Biol Pharm Bull. 2013;36(1):48-54
pubmed: 23302636
J Genet Genomics. 2019 Nov 20;46(11):513-521
pubmed: 31911131
AAPS J. 2010 Dec;12(4):492-503
pubmed: 20544328
Transl Res. 2022 Apr;242:38-55
pubmed: 34871810
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Nat Biotechnol. 2017 Mar;35(3):222-229
pubmed: 28244992
Circ Res. 2014 May 9;114(10):1569-75
pubmed: 24663402
Nat Biotechnol. 2022 Jun;40(6):840-854
pubmed: 35534554
Adv Drug Deliv Rev. 2021 Dec;179:114002
pubmed: 34653534
J Cardiovasc Pharmacol Ther. 2017 May;22(3):273-282
pubmed: 27811197
Front Bioeng Biotechnol. 2021 Mar 18;9:628137
pubmed: 33816449
Eur J Heart Fail. 2018 Jan;20(1):78-85
pubmed: 29027324
Mol Med Rep. 2018 Mar;17(3):4736-4746
pubmed: 29344661
Acc Chem Res. 2021 Nov 2;54(21):4012-4023
pubmed: 34677064
Sci Transl Med. 2021 Dec;13(622):eabe8952
pubmed: 34851694
Nat Commun. 2017 Nov 20;8(1):1614
pubmed: 29158499
Nat Rev Genet. 2022 May;23(5):265-280
pubmed: 34983972
Eur J Heart Fail. 2013 Jun;15(6):650-9
pubmed: 23388090
Cardiovasc Res. 2017 May 01;113(6):633-643
pubmed: 28453726
Nucleic Acids Res. 2019 Jul 26;47(13):6900-6916
pubmed: 31165876
Circulation. 2014 Mar 4;129(9):1009-21
pubmed: 24429688
Cancer Gene Ther. 2016 Apr;23(4):73-82
pubmed: 26987292
Exp Mol Med. 2022 Apr;54(4):455-465
pubmed: 35440755
Nat Biotechnol. 2013 Oct;31(10):898-907
pubmed: 24013197
Nat Commun. 2021 Aug 30;12(1):5180
pubmed: 34462437
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705